Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)
Issued Date
2023-09-01
Resource Type
eISSN
1791244X
Scopus ID
2-s2.0-85165455710
Pubmed ID
37477132
Journal Title
International journal of molecular medicine
Volume
52
Issue
3
Rights Holder(s)
SCOPUS
Bibliographic Citation
International journal of molecular medicine Vol.52 No.3 (2023)
Suggested Citation
Thongchot S., Aksonnam K., Thuwajit P., Yenchitsomanus P.T., Thuwajit C. Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). International journal of molecular medicine Vol.52 No.3 (2023). doi:10.3892/ijmm.2023.5284 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/88259
Title
Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)
Author's Affiliation
Other Contributor(s)
Abstract
The benefits of treating several types of cancers using immunotherapy have recently been established. The overexpression of nucleolin (NCL) in a number of types of cancer provides an attractive antigen target for the development of novel anticancer immunotherapeutic treatments. NCL is a multifunctional protein abundantly distributed in the nucleus, cytoplasm and cell membrane. It influences carcinogenesis, and the proliferation, survival and metastasis of cancer cells, leading to cancer progression. Additionally, the meta‑analysis of total and cytoplasmic NCL overexpression indicates a poor prognosis of patients with breast cancer. The AS1411 aptamers currently appear to have therapeutic action in the phase II clinical trial. The authors' research group has recently explored the anticancer function of NCL through the activation of T cells by dendritic cell‑based immunotherapy. The present review describes and discusses the mechanisms through which the multiple functions of NCL can participate in the progression of cancer. In addition, the studies that define the utility of NCL‑dependent anticancer therapies are summarized, with specific focus being paid to cancer immunotherapeutic approaches.